Filing Details
- Accession Number:
- 0000899243-16-013156
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2016-02-11 19:45:58
- Reporting Period:
- 2016-02-09
- Filing Date:
- 2016-02-11
- Accepted Time:
- 2016-02-11 19:45:58
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1260837 | C Barry Johnson | One Idexx Drive Westbrook ME 04092 | Yes | No | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2016-02-09 | 9,054 | $17.19 | 12,614 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2016-02-09 | 9,054 | $68.90 | 3,560 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Non-Qualified Stock Option (right-to-buy) | Disposition | 2016-02-09 | 9,054 | $0.00 | 9,054 | $17.19 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2016-02-13 | No | 4 | M | Direct |
Footnotes
- The number of securities reported reflects a 2-for-1 stock split in the form of a 100% stock dividend on IDEXX Laboratories, Inc. common stock paid on June 15, 2015 (the "Stock Split").
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $68.90 to $68.93 inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of option to buy shares of IDEXX Laboratories, Inc. common stock that became exercisable as to 4,527 shares on February 14, 2010, without giving effect to the 2-for-1 "Stock Split". The number of derivative securities reported as beneficially owned with respect to this option and its exercise price were adjusted to reflect the Stock Split.
- Not applicable.
Billionaire Hedge Funds
